<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: Traditional <z:chebi fb="23" ids="18059">lipid</z:chebi> indices have been associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, but limited data are available regarding non-<z:chebi fb="6" ids="39025">high-density lipoprotein</z:chebi> (non-<z:chebi fb="17" ids="39025">HDL</z:chebi>) cholesterol </plain></SENT>
<SENT sid="1" pm="."><plain>In view of recent guidelines for the clinical management of <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> recommending the monitoring of non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> as a secondary target after achieving the <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>) cholesterol goal, we aimed to assess the association of non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> with incident type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and compare its utility as a risk predictor with traditional <z:chebi fb="23" ids="18059">lipid</z:chebi> variables in Aboriginal Canadians </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Of 606 <z:mp ids='MP_0002055'>diabetes</z:mp>-free participants at baseline, 540 (89.1%) returned for 10-year follow-up assessments </plain></SENT>
<SENT sid="3" pm="."><plain>Baseline anthropometry, blood pressure, fasting insulin and serum <z:chebi fb="23" ids="18059">lipids</z:chebi> were measured </plain></SENT>
<SENT sid="4" pm="."><plain>Fasting and 2-h postload <z:chebi fb="105" ids="17234">glucose</z:chebi> were obtained at baseline and follow-up to determine the incidence of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The cumulative incidence of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> was 17.5% </plain></SENT>
<SENT sid="6" pm="."><plain>Higher non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>, total-to-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> ratio, <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B, <z:chebi fb="0" ids="17855">triglyceride</z:chebi> and <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> and lower <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> concentrations were individually associated with incident type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in univariate analyses (<z:hpo ids='HP_0000001'>all</z:hpo> p &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>Non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> was a superior determinant of incident <z:mp ids='MP_0002055'>diabetes</z:mp> compared with <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> (comparing C-statistics of univariate models p = 0.01) or <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> (p = 0.004) </plain></SENT>
<SENT sid="8" pm="."><plain>With multivariate adjustment including waist circumference, non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> remained associated with incident <z:mp ids='MP_0002055'>diabetes</z:mp> [odds ratio (OR) 1.42 (95% confidence interval, CI 1.07-1.88)], while <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> and <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> became non-significant </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> was associated with incident type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and was superior to <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> as a risk predictor in this population </plain></SENT>
<SENT sid="10" pm="."><plain>Further studies are required to establish the utility of non-<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> in non-Aboriginal populations </plain></SENT>
</text></document>